These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 20373871)

  • 1. Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.
    Zhang J; Chen YH; Lu Q
    Future Oncol; 2010 Apr; 6(4):587-603. PubMed ID: 20373871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
    Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
    Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer.
    O'Bryan S; Dong S; Mathis JM; Alahari SK
    Eur J Cancer; 2017 Feb; 72():1-11. PubMed ID: 27997852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction pathways: new targets in oncology.
    Sweeb RK; Beijnen JH
    Pharm World Sci; 1993 Dec; 15(6):233-42. PubMed ID: 8298582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Developmental Pathways: The Achilles Heel of Cancer?
    Dempke WCM; Fenchel K; Uciechowski P; Chevassut T
    Oncology; 2017; 93(4):213-223. PubMed ID: 28738360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics.
    Islam MT; Chen F; Chen H
    Arch Biochem Biophys; 2021 Apr; 701():108811. PubMed ID: 33600786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional perspective of nitazoxanide as a potential anticancer drug.
    Di Santo N; Ehrisman J
    Mutat Res; 2014 Oct; 768():16-21. PubMed ID: 25847384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy.
    Zada S; Hwang JS; Ahmed M; Lai TH; Pham TM; Elashkar O; Kim DR
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188565. PubMed ID: 33992723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Mechanisms of Action of Curcumin for Cancer Prevention: Focus on Cellular Signaling Pathways and miRNAs.
    Wang M; Jiang S; Zhou L; Yu F; Ding H; Li P; Zhou M; Wang K
    Int J Biol Sci; 2019; 15(6):1200-1214. PubMed ID: 31223280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomodulin-1, a synthetic peptide abrogates oncogenic signaling pathways to impede invasion and angiogenesis in the hamster cheek pouch carcinogenesis model.
    Kavitha K; Kranthi Kiran Kishore T; Bhatnagar RS; Nagini S
    Biochimie; 2014 Jul; 102():56-67. PubMed ID: 24582832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPAG5: An Emerging Oncogene.
    He J; Green AR; Li Y; Chan SYT; Liu DX
    Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
    Kobayashi Y; Lim SO; Yamaguchi H
    Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G Protein-Coupled Receptors in cancer: biochemical interactions and drug design.
    Audigier Y; Picault FX; Chaves-Almagro C; Masri B
    Prog Mol Biol Transl Sci; 2013; 115():143-73. PubMed ID: 23415094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the transforming growth factor-beta signaling pathway in human cancer.
    Nagaraj NS; Datta PK
    Expert Opin Investig Drugs; 2010 Jan; 19(1):77-91. PubMed ID: 20001556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo signaling pathway provides novel anti-cancer drug targets.
    Bae JS; Kim SM; Lee H
    Oncotarget; 2017 Feb; 8(9):16084-16098. PubMed ID: 28035075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.